(Q44234517)

1 December 2017

Combination of vascular targeting agents with thermal or radiation therapy (English)

1 reference

1 December 2017

0 references

Michael R Horsman

1

0 references

author name string

Rumi Murata

series ordinal

2

1 reference

PubMed ID

12459380

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

International Journal of Radiation Oncology Biology Physics

1 December 2017

1 reference

1 December 2017

54

1 reference

1 December 2017

1518-1523

1 reference

1 December 2017

5

1 reference

Vascular attack as a therapeutic strategy for cancer

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Targeting tumor blood vessels: an adjuvant strategy for radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

The in vivo interaction between flavone acetic acid and hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Combined treatment of IL-1 alpha and TNF-alpha potentiates the antitumour effect of hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

The use of hydralazine to manipulate tumour temperatures during hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

The Influence of Hypoxia and Acidity on the Hyperthermic Response of Malignant CellsIn Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903926-3

7 January 2021

10.1016/S0360-3016(02)03926-3

Identifiers

DOI

1 reference

1 December 2017

1 reference

PubMed ID

12459380